Global Human Plasma-Derived Therapeutics Market Size By Type (Albumin, Immunoglobulin), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Human Plasma-Derived Therapeutics Market was valued at USD 30.5 billion in 2023 and is projected to reach USD 51.7 billion by 2031, growing at a CAGR of 6.8% during the forecast period from 2023 to 2031. The market growth is primarily driven by the increasing prevalence of rare and chronic diseases, rising demand for immunoglobulins and coagulation factors, and the expanding plasma collection infrastructure worldwide.

Human plasma-derived therapeutics are critical for treating various life-threatening conditions, including immune deficiencies, bleeding disorders, and neurological diseases. The surge in investments in plasma fractionation facilities, coupled with favorable government policies supporting plasma donation and research, is further propelling market growth.

Drivers:

Rising Prevalence of Chronic and Rare Diseases:

The growing incidence of primary immunodeficiency diseases (PIDs), hemophilia, and neurological disorders has significantly increased the demand for plasma-derived therapies worldwide.

Expansion of Plasma Collection Centers:

Ongoing investments in the establishment of plasma collection centers and increased donor awareness campaigns are driving plasma supply, enabling market growth.

Technological Advancements in Plasma Fractionation:

Innovations in plasma fractionation technologies are improving therapeutic yields, purity, and safety, supporting the efficient production of advanced plasma-derived products.

Restraints:

High Production Costs:

The complex manufacturing process of plasma-derived products, which includes stringent regulatory requirements and long production cycles, results in high costs, posing a challenge for market expansion.

Risk of Plasma Supply Shortages:

Dependence on human plasma donations makes the market vulnerable to supply chain disruptions and regional shortages, especially during pandemics or health crises.

Opportunity:

Growing Demand in Emerging Economies:

Emerging markets such as India, China, and Brazil are witnessing increasing demand for plasma-derived therapeutics due to rising healthcare expenditure, expanding patient population, and improving healthcare infrastructure.

Development of New Therapeutic Indications:

Ongoing research and clinical trials exploring new therapeutic applications of plasma-derived products, such as for autoimmune diseases and novel neurological conditions, present significant market opportunities.

Market by System Type Insights:

Based on product type, the Immunoglobulin segment accounted for the largest market share in 2023. Immunoglobulins are extensively used to treat immune deficiencies, inflammatory diseases, and autoimmune disorders. The segment is expected to maintain its dominance due to the rising incidence of PIDs and favorable reimbursement policies.

Coagulation Factor Concentrates, particularly Factor VIII and Factor IX, are also witnessing robust growth due to their critical role in managing hemophilia and bleeding disorders.

Market by End-use Insights:

Hospitals & Clinics emerged as the leading end-use segment in 2023, contributing to over 50% of the market share. The availability of advanced therapeutic solutions and specialized treatment facilities in hospitals makes them the primary end-users of plasma-derived therapeutics.

Plasma Collection Centers are anticipated to grow significantly during the forecast period, driven by the expansion of plasma donation networks and the increasing adoption of plasma-derived therapies in outpatient settings.

Market by Regional Insights:

North America dominated the Global Human Plasma-Derived Therapeutics Market in 2023, supported by well-established plasma collection infrastructure, advanced healthcare systems, and strong regulatory frameworks.

Asia-Pacific is expected to register the highest CAGR during the forecast period, fueled by increasing healthcare investments, growing awareness of plasma donation, and a rising prevalence of rare diseases in countries like China and India.

Competitive Scenario:

Key players operating in the Global Human Plasma-Derived Therapeutics Market include:

CSL Behring

Grifols S.A.

Takeda Pharmaceutical Company Limited

Octapharma AG

Kedrion Biopharma

LFB Group

ADMA Biologics

Bio Products Laboratory

Sanquin

China Biologic Products Holdings Inc.

These companies are focusing on strategic acquisitions, capacity expansions, new product launches, and technological advancements to strengthen their market position.

Scope of Work – Global Human Plasma-Derived Therapeutics Market

Report Metric Details

Market Size (2023) USD 30.5 billion

Projected Market Size (2031) USD 51.7 billion

CAGR (2023-2031) 6.8%

Key Segments by Product Type Immunoglobulin, Coagulation Factor Concentrates, Albumin

Key Segments by End-use Hospitals & Clinics, Plasma Collection Centers

Leading Region North America

Key Players CSL Behring, Grifols S.A., Takeda, Octapharma AG, Kedrion Biopharma

Growth Drivers Rising Prevalence of Rare Diseases, Expansion of Plasma Collection Centers, Technological Advancements

Market Opportunities Demand Surge in Emerging Markets, New Therapeutic Indications for Plasma Products

Key Market Developments:

In January 2024, CSL Behring announced the expansion of its plasma fractionation facility in the U.S., aimed at increasing production capacity for immunoglobulin and albumin products.

In September 2023, Grifols launched a new immunoglobulin product approved for subcutaneous administration, enhancing patient convenience and adherence.

In 2022, Takeda Pharmaceutical Company Limited partnered with a biotechnology firm to develop next-generation plasma-derived therapies for rare autoimmune conditions.

FAQs:

1. What is the current market size of the Global Human Plasma-Derived Therapeutics Market?

The market was valued at USD 30.5 billion in 2023.

2. What is the major growth driver of the Global Human Plasma-Derived Therapeutics Market?

The rising prevalence of chronic and rare diseases, coupled with the expansion of plasma collection infrastructure, is a major growth driver.

3. Which is the largest region during the forecast period in the Global Human Plasma-Derived Therapeutics Market?

North America is expected to remain the largest region due to its advanced healthcare systems and established plasma collection network.

4. Which segment accounted for the largest market share in the Global Human Plasma-Derived Therapeutics Market?

The Immunoglobulin segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Human Plasma-Derived Therapeutics Market?

Key players include CSL Behring, Grifols S.A., Takeda Pharmaceutical Company Limited, Octapharma AG, and Kedrion Biopharma.